Year Book of RCC 2019

出版社： メディカルレビュー社
著者：
発行日： 2019-12-31
分野： 臨床医学：内科  >  腎臓
ISBN： 9784779222924
電子書籍版： 2019-12-31 （第1版第1刷）
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,280 円(税込)

購入する

商品紹介

腎細胞癌に関する現時点での知見と、現場の感覚を失わない「本当のところ」がわかる1冊。

目次

  • 表紙
  • 序文
  • Contents
  • Author List
  • I Round Table Discussion
  • II Topics of RCC Yes or No - cytoreductive nephrectomy -
  • 1 Overview : 転移性RCCに対するcytoreductive nephrectomyの歴史的変遷
  • 2 Case Base Debate ( 1 ) : Upfrontのcytoreductive nephrectomy
  • 1) Yes : 行うべき
  • 2) No : 慎重であるべき
  • 3 Case Base Debate ( 2 ) : 治療経過中のcytoreductive nephrectomy
  • 1) Yes : 行うべき
  • 2) No : 慎重であるべき
  • III TKI up to date 新規TKIへの展望と期待
  • 1 Overview : RCC治療におけるこれまでのTKI治療の総括と現状
  • 2 Cabozantinib
  • 1) 開発の経緯とRCC以外の癌腫での状況
  • 2) RCCでの状況
  • 3 レンバチニブ
  • IV 付録
  • RCC関連演題の一覧 ( ASCO 2019, AUA 2019, ESMO 2019 )
  • 索引
  • 編集者プロフィール
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I Round Table Discussion

P.17 掲載の参考文献
1) Tawbi HA, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018 ; 379 : 722-30.
 
2) Flippot R, et al. Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma : Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. J Clin Oncol. 2019 ; 37 : 2008-16.
PubMed
3) Motzer RJ, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 ; 378 : 1277-90.
PubMed

II Topics of RCC Yes or No - cytoreductive nephrectomy -

P.29 掲載の参考文献
1) Flanigan RC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001 ; 345 : 1655-9.
PubMed
2) Mickisch GH, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma : a randomised trial. Lancet. 2001 ; 358 : 966-70.
PubMed
3) Heng DY, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma : results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014 ; 66 : 704-10.
PubMed
4) Choueiri TK, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011 ; 185 : 60-6.
PubMed
5) Hanna N, et al. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy : A National Cancer Data Base Study. J Clin Oncol. 2016 ; 34 : 3267-75.
PubMed
6) Tatsugami K, et al. Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era. Int J Urol. 2015 ; 22 : 736-40.
PubMed
7) You D, et al. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J Urol. 2011 ; 185 : 54-9.
PubMed
8) Conti SL, et al. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer. 2014 ; 134 : 2245-52.
PubMed
9) Day D, et al. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-tolymphocyte ratio in patients with metastatic renal cell carcinoma. Intern Med J. 2016 ; 46 : 1291-7.
 
10) de Groot S, et al. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy : Results From a Population-based Registry. Urology. 2016 ; 95 : 121-7.
PubMed
11) Patel MI, et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma : inequities in access exist despite improved survival. Cancer Med. 2017 ; 6 : 2188-93.
PubMed
12) Klatte T, et al. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma : a comparative study using inverse probability of treatment weighting. World J Urol. 2018 ; 36 : 417-25.
PubMed
13) Bhindi B, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond : An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol. 2019 ; 75 : 111-28.
PubMed
14) Mejean A, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018 ; 379 : 417-27.
 
15) Mejean A, et al. Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC) : Update on Carmena trial with focus on intermediate IMDC-risk population [abstract]. J Clin Oncol. 2019 ; 37 Suppl : 4508.
 
16) Motzer RJ, et al. Cytoreductive Nephrectomy-Patient Selection Is Key. N Engl J Med. 2018 ; 379 : 481-2.
 
17) Bex A, et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib : The SURTIME Randomized Clinical Trial. JAMA Oncol. 2019 ; 5 : 164-70.
PubMed
18) De Bruijn RE, et al. Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib : Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME). Eur Urol. 2019 ; 76 : 437-40.
PubMed
19) Kassouf W, et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol. 2007 ; 178 : 1896-900.
PubMed
20) Graham J, et al. Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma : Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. 2019 [Epub ahead of print]
 
21) Marchioni M, et al. Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients : A Population-based Study. Eur Urol Focus. 2019 ; 5 : 488-96.
PubMed
22) Psutka SP, et al. Reassessing the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in 2019. Am Soc Clin Oncol Educ Book. 2019 ; 39 : 276-83.
PubMed
P.35 掲載の参考文献
1) Mickisch GH, et al ; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma : a randomised trial. Lancet. 2001 ; 358 : 966-70.
PubMed
2) Flanigan RC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001 ; 345 : 1655-9.
PubMed
3) Mejean A, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018 ; 379 : 417-27.
 
4) Bex A, et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib : The SURTIME Randomized Clinical Trial. JAMA Oncol. 2019 ; 5 : 164-70.
PubMed
5) Mejean A, et al. Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC) : Update on Carmena trial with focus on intermediate IMDC-risk population [abstract]. J Clin Oncol. 2019 ; 37 Suppl : 4508.
 
6) Cost NG, et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011 ; 59 : 912-8.
PubMed
7) Bigot P, et al. Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy : is it useful? World J Urol. 2014 ; 32 : 109-14.
PubMed
P.41 掲載の参考文献
1) Mejean A, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018 ; 379 : 417-27.
 
2) Fallick ML, et al. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol. 1997 ; 158 : 1691-5.
PubMed
3) Motzer RJ, et al. Cytoreductive Nephrectomy-Patient Selection Is Key. N Engl J Med. 2018 ; 379 : 481-2.
 
4) Bex A, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib : The SURTIME randomized clinical trial. JAMA Oncol. 2019 ; 5 : 164-70.
PubMed
5) Culp SH, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010 ; 116 : 3378-88.
PubMed
6) Psutka SP, et al. The impact of targeted therapy on management of metastatic renal cell carcinoma : trends in systemic therapy and cytoreductive nephrectomy utilization. Urology. 2015 ; 85 : 442-50.
 
7) Petrelli F, et al. Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies : A Systematic Review With a Meta-Analysis. Clin Genitourin Cancer. 2016 ; 14 : 465-72.
PubMed
8) Bhindi B, et al. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma. J Urol. 2018 ; 200 : 528-34.
PubMed
9) Arora S, et al. Cytoreductive Nephrectomy : Assessing the Generalizability of the CARMENA Trial to Real-world National Cancer Data Base Cases. Eur Urol. 2019 ; 75 : 352-3.
PubMed
10) Motzer RJ, et al ; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 ; 378 : 1277-90.
PubMed
11) Flanigan RC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001 ; 345 : 1655-9.
PubMed
12) Mickisch GH, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma : a randomised trial. Lancet. 2001 ; 358 : 966-70.
PubMed
P.48 掲載の参考文献
1) Flanigan RC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001 ; 345 : 1655-9.
PubMed
2) Mickisch GH, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma : a randomised trial. Lancet. 2001 ; 358 : 966-70.
PubMed
3) Heng DY, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma : results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014 ; 66 : 704-10.
PubMed
4) Mejean A, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018 ; 379 : 417-27.
 
5) Bex A, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib : The SURTIME randomized clinical trial. JAMA Oncol. 2019 ; 5 : 164-70.
PubMed
P.54 掲載の参考文献
1) Mejean A, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018 ; 379 : 417-27.
 
2) Bex A, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib : The SURTIME randomized clinical trial. JAMA Oncol. 2019 ; 5 : 164-70.
PubMed
3) Mickisch GH, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma : a randomised trial. Lancet. 2001 ; 358 : 966-70.
PubMed
4) Flanigan RC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001 ; 345 : 1655-9.
PubMed
5) Ivanyi P, et al. Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival? World J Urol. 2016 ; 34 : 909-15.
PubMed
6) Bhindi B, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond : An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol. 2019 ; 75 : 111-28.
PubMed
7) Heng DY, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma : results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014 ; 66 : 704-10.
PubMed
8) National Comprehensive Cancer Network. NCCN Guidelines, Kidney Cancer, Version 2. 2020. https://www.nccn.org/professionals/physician_gls/default.aspx, (accessed 2019-11-01)
 
9) Ljungberg B, et al. EAU Guidelines on Renal Cell Carcinoma. https://uroweb.org/guideline/renal-cell-carcinoma/, (accessed 2019-11-01)
 
10) 日本泌尿器科学会. 腎癌診療ガイドライン 2017年版 補足. 2019-05. https://www.urol.or.jp/lib/files/other/guideline/33_renal_cancer_2017_rev2019_info.pdf, (閲覧 : 2019-11-01)
 

III TKI up to date 新規TKIへの展望と期待

P.63 掲載の参考文献
1) Rini BI, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011 ; 103 : 763-73.
PubMed
2) Kawashima A, et al. One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients. Eur J Cancer. 2011 ; 47 : 1521-6.
PubMed
3) 中山雅志, 他. スニチニブの血中トラフ濃度は個人差が大きい [abstract]. 第104回日本泌尿器科学会総会. 仙台. 2016 : PP3-180.
 
4) Miura Y, et al. Individualized Dosing of Axitinib Based on First-Dose Area Under the Concentration-Time Curve for Metastatic Renal-Cell Carcinoma. Clin Genitourin Cancer. 2019 ; 17 : e1-11.
PubMed
5) Escudier B, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 ; 356 : 125-34.
PubMed
6) Escudier B, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 ; 27 : 1280-9.
PubMed
7) Eichelberg C, et al. SWITCH : A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. Eur Urol. 2015 ; 68 : 837-47.
PubMed
8) Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 ; 356 : 115-24.
PubMed
9) Motzer RJ, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 ; 27 : 3584-90.
PubMed
10) Motzer RJ, et al. Phase II randomized trial comparing sequential first-line everolimus and secondline sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014 ; 32 : 2765-72.
 
11) Atkinson BJ, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN) : a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016 ; 17 : 378-88.
 
12) Armstrong AJ, et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 2014 ; 191 : 611-8.
 
13) Mouillet G, et al. Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma : study protocol of the SURF trial. Trials. 2018 ; 19 : 221.
 
14) Motzer RJ, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 ; 378 : 1277-90.
PubMed
15) Rini BI, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS) : a randomised phase 3 trial. Lancet. 2011 ; 378 : 1931-9.
 
16) Motzer RJ, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma : overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013 ; 14 : 552-62.
PubMed
17) Ueda T, et al. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma : subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Jpn J Clin Oncol. 2013 ; 43 : 616-28.
PubMed
18) Sternberg CN, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma : results of a randomized phase III trial. J Clin Oncol. 2010 ; 28 : 1061-8.
 
19) Sternberg CN, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma : final overall survival results and safety update. Eur J Cancer. 2013 ; 49 : 1287-96.
PubMed
20) Motzer RJ, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013 ; 369 : 722-31.
PubMed
21) Escudier B, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma. PISCES Study. J Clin Oncol. 2014 ; 32 : 1412-8.
PubMed
22) Motzer RJ, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 ; 380 : 1103-15.
PubMed
23) Rini BI, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 ; 380 : 1116-27.
PubMed
24) Rini BI, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151) : a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019 ; 393 : 2404-15.
PubMed
P.70 掲載の参考文献
1) Tannir NM, et al. Cabozantinib : an active novel multikinase inhibitor in renal cell carcinoma. Curr Oncol Rep. 2017 ; 19 : 14.
 
2) Firtina Karagonlar Z, et al. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. Cancer Sci. 2016 ; 107 : 407-16.
PubMed
3) Schoumacher M, et al. Key roles of AXL and MER receptor tyrosine kinases in resistance to multiple anticancer therapies. Curr Oncol Rep. 2017 ; 19 : 19.
 
4) Ruiz-Morales JM, et al. Cabozantinib in the treatment of advanced renal cell carcinoma : clinical trial evidence and experience. Ther Adv Urol. 2016 ; 8 : 338-47.
PubMed
5) You WK, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 2011 ; 71 : 4758-68.
 
6) Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011 ; 10 : 2298-308.
PubMed
7) Kumar R, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer. 2009 ; 101 : 1717-23.
PubMed
8) Hu-Lowe DD, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008 ; 14 : 7272-83.
PubMed
9) Bottaro DP, et al. Identification of the hepatocyte growth factor receptor as the c-met protooncogene product. Science. 1991 ; 251 : 802-4.
 
10) Cecchi F, et al. Targeting the HGF/Met signaling pathway in cancer. Eur J Cancer. 2010 ; 46 : 1260-70.
 
11) Peruzzi B, et al. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res. 2006 ; 12 : 3657-60.
 
12) Neubauer A, et al. Recent progress on the role of Axl, a receptor tyrosine kinase, in malignant transformation of myeloid leukemias. Leuk Lymphoma. 1997 ; 25 : 91-6.
PubMed
13) Gay CM, et al. Giving AXL the axe : targeting AXL in human malignancy. Br J Cancer. 2017 ; 116 : 415-23.
PubMed
14) Rapisarda A, et al. Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res. 2012 ; 114 : 237-67.
PubMed
15) Sulpice E, et al. Cross-talk between the VEGF-A and HGF signaling pathways in endothelial cells. Biol Cell. 2009 ; 101 : 525-39.
PubMed
16) Rho JK, et al. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res. 2014 ; 74 : 253-62.
PubMed
17) Blanc J, et al. Type II kinase inhibitors : an opportunity in cancer for rational design. Anticancer Agents Med Chem. 2013 ; 13 : 731-47.
PubMed
18) Abou-Alfa GK, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018 ; 379 : 54-63.
PubMed
19) Kelley RK, et al. Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy [abstract]. J Clin Oncol. 2019 ; 37 Suppl : TPS4157.
 
20) Elisei R, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 ; 31 : 3639-46.
PubMed
21) Schoffski P, et al. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. Eur J Cancer. 2017 ; 86 : 296-304.
PubMed
22) Smith M, et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer : COMET-1. J Clin Oncol. 2016 ; 4 : 3005-13.
PubMed
23) Pal SK, et al. Phase Ib (COSMIC-021) trial of cabozantinib (C) in urothelial carcinoma (UC) or C in combination with atezolizumab (A) in patients (pts) with UC, castrate resistant prostate cancer (CRPC) or renal cell carcinoma (RCC) [ abstract]. J Clin Oncol. 2019 ; 37 Suppl : TPS683.
 
24) Nadal RM, et al. Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies [abstract]. J Clin Oncol. 2018 ; 36 Suppl : 515.
 
25) Hellerstedt BA, et al. Results of a phase II placebo-controlled randomized discontinuation trial of cabozantinib in patients with non-small-cell lung carcinoma. Clin Lung Cancer. 2019 ; 20 : 74-81.
PubMed
26) Reckamp KL, et al. Phase II Trial of cabozantinib plus erlotinib in patients with advanced epidermal growth factor receptor (EGFR) -mutant non-small cell lung cancer with progressive disease on epidermal growth factor receptor tyrosine kinase inhibitor therapy : a California cancer consortium phase II trial (NCI 9303). Front Oncol. 2019 ; 9 : 132.
PubMed
27) Strickler JH, et al. Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC) [abstract]. J Clin Oncol. 2016 ; 34 Suppl : 3548.
 
P.77 掲載の参考文献
1) Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011 ; 10 : 2298-308.
PubMed
2) Choueiri TK, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015 ; 373 : 1814-23.
PubMed
3) Choueiri TK, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR) : final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 ; 17 : 917-27.
PubMed
4) Powles T, et al. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer. 2018 ; 119 : 663-9.
PubMed
5) Choueiri TK, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk : the alliance A031203 CABOSUN Trial. J Clin Oncol. 2017 ; 35 : 591-7.
 
6) Choueiri TK, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial) : Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018 ; 94 : 115-25.
 
7) Amin A, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma : the CheckMate 016 study. J Immunother Cancer. 2018 ; 6 : 109.
 
8) Nadal RM, et al. Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies [abstract]. J Clin Oncol. 2018 ; 36 Suppl : 515.
 
9) Zhang X, et al. Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. BMC Cancer. 2019 ; 19 : 360.
 
10) Choueiri TK, et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib : results from COMPARZ, a randomized controlled trial. Clin Cancer Res. 2015 ; 21 : 1071-7.
 
11) Motzer RJ, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 ; 378 : 1277-90.
PubMed
12) Flaifel A, et al. PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma : Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clin Cancer Res. 2019 ; 25 : 6080-8.
PubMed
P.83 掲載の参考文献
1) Tsimafeyeu I, et al. Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma. Scand J Urol Nephrol. 2011 ; 45 : 190-5.
PubMed
2) Yamamoto Y, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014 ; 6 : 18.
PubMed
3) Matsuki M, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018 ; 7 : 2641-53.
PubMed
4) Motzer RJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma : an open-label, randomised phase 3 trial. Lancet Oncol. 2014 ; 15 : 286-96.
PubMed
5) Boss DS, et al. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer. 2012 ; 106 : 1598-604.
PubMed
6) Motzer RJ, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma : a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015 ; 16 : 1473-82.
PubMed
7) Hutson TE, et al. Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol. 2016 ; 34 Suppl : 4553.
 
8) Kimura T, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 2018 ; 109 : 3993-4002.
PubMed
9) Makker V, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer : an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019 ; 20 : 711-8.
PubMed
10) Grunwald V, et al. Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma : study design and rationale. Future Oncol. 2019 ; 15 : 929-41.
 
11) National Comprehensive Cancer Network. NCCN Guidelines, Kidney Cancer, Version 2. 2020. https://www.ccn.org/professionals/phys免疫チェックポイント阻害薬an_gls/default.aspx, (accessed 2019-09-25)
 
12) Escudier B, et al. Renal cell carcinoma : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 ; 30 : 706-20.
PubMed
13) Albiges L, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clearcell Renal Cell Carcinoma. Eur Urol. 2019 ; 76 : 151-6.
PubMed

書評

最近チェックした商品履歴

Loading...